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Two-Stage and Weibull Models for
Carcinogenesis Applied to the ED01
Discontinued Dosing Data
by Ralph L. Kodell* and R. Paul Feltont
The two-stage clonal expansion model for a single, less-than-lifetime period of dosing is
formulated and applied to the liver and bladder tumor data from the EDMo study. The model suc-
cessfully predicts liver tumor incidence for time points beyond termination of dosing with
2-acetylaminofluorene, but it is unsuccessful for bladder tumor incidence. A discontinued dos-
ing version ofthe Weibull model is proposed and is shown to predict successfully both liver and
bladder tumor incidences for time points after termination ofdosing.
Introduction
The ED,,1 study (1) was conducted at the National
Center for Toxicological Research (NCTR) for the pur-
pose of establishing the shape of the tumorigenic dose-
response curve for 2-acetylaminofluorene (2-AAF) at
low doses (i.e., doses in the neighborhood of a 1% re-
sponse rate). It was found that for the two primary
carcinogenic responses, hepatocellular neoplasms of
the liver and carcinomas of the bladder, distinctly dif-
ferent dose-response relationships occurred under a
continuous dosing regimen. Whereas the tumorigenic
dose response in the liver was nearly linear, that in the
bladder was decidedly nonlinear. These contrasting
shapes were observed at various points during the life-
times of the BALB/c female mice that were used as
test animals (1).
One aspect of the ED,1 study that, in addition to its
size, sets it apart from most other carcinogenesis bioas-
says is its inclusion of groups of animals for which dos-
ing with the test chemical was discontinued several
months prior to sacrifice. These groups are useful for
advancing theories about the carcinogenic process. In-
deed, Littlefield et al. (2) postulated the precursor role
*Biometry Staff, National Center for Toxicological Research,
Jefferson, AR 72079-9502.
tComputer Based Systems, Inc., National Center for Toxicological
Research, Jefferson, AR 72079-9502.
Address reprint requests to R. L. Kodell, Biometry Staff, HFT-20,
National Center for Toxicological Research, NCTR Drive, Jefferson,
AR 72079-9502.
of "persistent" hyperplasia in 2-AAF-induced bladder
cancer using information from the discontinued dosing
groups. Day and Brown (3), working within the theo-
retical framework ofthe multistage model (4), observed
that the discontinued dosing responses were consistent
with the characterization of 2-AAF as an early-stage
carcinogen in the liver and a late-stage carcinogen in
the bladder.
Formal mathematical modeling of the ED,,1 study's
discontinued dosing data was first done by Brown and
Hoel (5). They derived a mathematical expression for
the multistage model under discontinued dosing and fit
it to the liver tumor prevalence data observed in sacri-
ficed animals. They did not attempt to model the bladder
tumor data, due to low responses in many treatment
groups. Brown and Hoel (5) found the liver tumor
prevalence data to be consistent with both a multistage
model with four total stages, two stages being dose re-
lated, and a multistage model with six total stages, only
one stage being dose related. Freedman and Navidi (6)
included the ED,,1 data among various data sets that
they examined in the context of the multistage model.
Whereas their data selection and assumptions were
slightly different from those of Brown and Hoel (5),
Freedman and Navidi (6) found a multistage model with
seven total stages, two being dose related, to give the
best prediction ofliver tumor response rates in the dis-
continued treatment groups. They were unable to find
a version of the multistage model that would fit a se-
lected portion of the continuous dosing bladder tumor
data and successfully predict bladder tumor responses
in the discontinued dosing groups. Chiang and ConfortiKODELL AND FELTON
(7) postulated a new model for time to onset of the
tumorigenic response, including a version to describe
discontinued dosing data. Working with only the EDO,
bladder tumor data, they were unable to predict consis-
tently the observed responses in the discontinued dos-
ing groups.
Although previous investigators have been able to
describe successfully the EDO, discontinued dosing liver
tumor responses within the framework ofthe multistage
model, none has yet modeled successfully the EDo0
bladder tumor data for discontinued dosing. Indeed, it
has been shown that acceptable model fitting for con-
tinuous dosing data cannot be taken to imply correctness
of the model for extrapolating to discontinued dosing
situations (6,7). The purpose ofthis paper is to investi-
gate the currently popular two-stage clonal expansion
model (8,9) with respect to its ability to describe the
EDO, discontinued dosing data. The success of such
modeling would perhaps enable the characterization of
2-AAF-induced liver and bladdertumorigenesis in terms
of initiation, promotion, and completion (progression)
(10). At any rate, successful prediction of bladder tu-
mor responses for discontinued dosing groups by the
two-stage clonal expansion model would add to its
growing acceptance for carcinogenesis dose-response
modeling.
Two-Stage Clonal Expansion Model
In recent years there has been movement away from
the multistage model toward a model with only two
distinct stages (e.g., two mutations or other genetic
events) but with proliferation of cells that have under-
gone the first stage. One popular formulation of the
model was proposed by Moolgavkar and his co-workers
(8,11). Another widely recognized version of the two-
stage clonal expansion model has been developed and
applied by Greenfield et al. (9). As pointed out by Bogan
(12), the original two-stage model formulated by
Armitage and Doll (13) provided for cell proliferation.
However, the most widely studied and applied version
of the multistage model does not (4). Whereas the
growth of cells that have undergone the first stage in
the two-stage clonal expansion model is exponential,
Bogen (12) argued that geometric growth appeared to
provide a better representation of certain data sets. In
this paper; the two-stage model with exponential cell
growth will be studied, with the terminology of Thors-
lund et al. (10) being used to characterize carcinogenic
action. Specifically, carcinogenic action will be modeled
in terms of initiation, promotion, and completion (pro-
gression), where initiation and completion refer to the
occurrence of the first- and second-stage events, re-
spectively, in the two-stage model, and promotion
refers to the growth ofinitiated cells.
For continuous exposure to a carcinogenic agent at a
dose rate d between time 0 and time t, the instantaneous
hazard (or age-specific incidence) rate ofthe two-stage
model with exponential growth ofinitiated cells may be
written as
t
h(d,t) = I X<(d,u) 2(d,t) N(u)
0
t
exp( I g(d,v)dv) du, O<t
u
where X, and k2represent, respectively, the rates ofoc-
currence of the first- and second-stage genetic events,
6 represents the net birth minus death rate of first-
stage cells, and N is the number of normal cells at risk
of a flrst-stage event. The cumulative hazard function
is
t
B(d,t) I h(d,u) du, O<t
0
Whereas the genetic event rates and the cell growth
rates may conceivably take various functional forms,
the usual assumption is made here that they are inde-
pendent oftime and linear in dose. Thus X1(d,t) = oc,+Pjdq
X2(d,t) = oc2+P2d and 6(d,t) = :c;+I3d. Furthermore, it is
assumed that the number of normal cells at risk is so
large that it may reasonably be regarded as constant.





{exPI[(a3+3d)t1 - 1 - (a3+Ad)t} , 0<t
For a single period of dosing at a constant rate d from
time 0 to time t1, followed by a period of discontinued
dosing up to time t, the cumulative hazard for the two-
stage clonal expansion model under the above formula-
tion is (see appendix)
B(d,t;0,t1) = (ai+Nd)(a2+02d)
(-3-133d)
{expI(a3+d)tli - 1 - (a3+03d)tj}
+ N -
(a3+13d) a3
{exPI(a3+A3d)tj1 - 1}{exPIa3(t-ti)J 1)
+ M _N
£3
{expIcI3(t-tj)il 1 - a3(t-tl)}, tI < t.
With this notation, the cumulative hazard under con-
tinuous dosing would be designated by H(d,t;0,t). Vari-
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ous special cases ofthe two-stage clonal expansion model
may be obtained by setting selected coefficients ofd(pi)
equal to zero in the continuous and discontinuous ver-
sions of the cumulative hazard function. The pure ini-
tiator model arises when P2 = P = 0, the pure completer
model when = l = 0, and the pure promoter model
when P = 2= 0 (14). The initiator-completer model
arises when P = 0, the initiator-promoter model when
12 = 0, and the promoter-completer model when 1P = 0.
Due to the fact that the rates of occurrence of the
two genetic events appear as a product in the two-stage
clonal expansion model, they are not, in general, sepa-
rately identifiable. For continuous dosing data only, the
models for pure initiator and pure completer are indis-
tinguishable, although they can be distinguished with
discontinued dosing data (14). The same is true for the
initiator-promoter and promoter-completer models.
Thus, if discontinued dosing data are available, then
the pure initiator, pure completer, initiator-promoter,
and promoter-completer models can all be resolved in
terms ofparameter estimation and model fit. However,
if parameters are estimated and goodness-of-fit is as-
certained using continuous data only, then extrapola-
tion to situations ofdiscontinued dosing, although it may
be carried out, is very dependent on which ofthe indis-
tinguishable continuous-dosing models is assumed. A
different extrapolation problem arises for the initiator-
completer model and for the full initiator-promoter-
completer model. Although these models are identifi-
able for both continuous dosing and discontinued dosing
data, the continuous dosing version of neither model
can be extrapolated to a discontinued dosing situation,
since individual parameters in the genetic event rates
are nonidentifiable. Only the pure promoter model is
uniquely identifiable irriespective ofthe dosing pattern.
EDO, Liver and Bladder Tumor Data
The ED,, study (1) was conducted in six animal rooms.
Each was set up as a replicate ofthe experiment, to be
loaded sequentially as animals became available from
the NCTR breeding colony. For the various continuous
dose groups (0, 30, 35, 45, 60, 75, 100, and 150 ppm 2-
AAF), interim sacrifices were scheduled at 9, 12, 14, 15,
16, 17, and 18 months on study, with the earliest sacri-
fices being omitted in the lowest dose groups. Due to
higher than expected survival and lower than expected
bladder tumor rates by the time ofthe 18-month sacrifice
in the first three rooms, some of the later scheduled
sacrifices (including 18 months) were rescheduled for
24 months in the last three rooms. Thus, the ED0,, study's
18-month sacrifice data came from the first three rooms
only, while its 24-month sacrifice data came from the
last three rooms only.
For the four highest dose levels of2-AAF, discontin-
ued dosing was included in the study's design. For each
of these dose levels, groups ofanimals received 2-AAF
for either 9, 12, or 15 months after which dosing was
discontinued until sacrifice. Sacrifices were all originally
scheduled for 18 months, but as indicated above, those
in the last three rooms were rescheduled for 24 months.
Previous modelers of the EDO, tumor data have used
various versions ofthe observed data for modeling pur-
poses. Brown and Hoel (5) used only the liver tumor
prevalence data observed in sacrificed animals, implic-
itly assuming that liver tumors were not related to the
deaths ofanimals that did not survive to scheduled sac-
rifice. Chiang and Conforti (7) used bladderl tumor rates
observed in combined sacrificed and dead/moribund
animals, also implicitly assuming no relationship between
bladder tumors and the deaths ofthe animals. Freedman
and Navidi (6) used bladderl and liver tumor prevalence
data from sacrificed animals as if the data were inci-
dence data, i.e., they assumed that tumors observed at
a sacrifice arose during the month of sacrifice. Since
the two-stage model with clonal expansion is, as are all
other models oftumorigenesis, a model for the distribu-
tion of time to onset of tumors, it is important that the
tumor data used for model fitting represent as closely
as possible the observed distribution of time to tumor
onset.
In this paper, the nonparametric estimator of Kodell
et al. (15) is used to adjust the observed tumor data
with respect to censoring by competing risks. Similar
acljustments have been proposed by Dinse and Lagakos
(16) andl Turnbull and Mitchell (17). With these meth-
ods, each animal's cause of death needs to have been
determined by the examining pathologist. One of the
strengths of the ED(,, pathology data is that cause of
death was reported for each animal that was removed
as deadl or moribund from the experiment. Hence, an
adjustment forc death from competing risks could be
made. With the method of Kodell et al. (15), the distri-
bution of time to tumor onset is estimated nonpara-
metrically for each dose group separately. Thus it is
possible to obtain dose-response information at any point
in time by using the value ofthe time to tumor distribu-
tion function from each dose group at that time. In the
present study, the time points ofprimary interest were
18 and 24 months, the sacrifice times in the discontin-
ued dosing groups. Both hepatocellular adenomas and
carcinomas were included as liver tumors, while only
carcinomas were included as bladder tumors.
The data used for model fitting are given in Tables 1
and 2 for liver and bladder tumors, respectively. P rep-
resents the nonparametric estimate of the probability
of tumor onset by time T (18 or 24 months), X is the
number of animals observed with tumors up to time T,
and N = X/P is the "effective" sample size. That is, for
given P, N is the number of animals that would have
been put on test initially, iftime to tumor onset of each
animal could have been observed, and if exactly X ani-
mals ofthe N would have developed tumors by time T.
Data on all dead, moribund, and sacrificed animals are
reflected in the numbers in Tables 1 and 2, even though
only times corresponding to sacrifices at 18 and 24
months have been selected for evaluation.
Due to the nesting ofthe 18- and 24-month sacrifices
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Table 1. ED,, liver tumor data adjusted for competing risks.
Rooms 141, 142, 143 combined" Rooms 144,145,146 combined'l
D' Ti' T' XI. T, T N X P
0 24 24 525 18 0.084 18 18 435 2 0.005
30 24 24 1432 114 0.080 18 18 1329 21 0.016
35 24 24 996 97 0.097 18 18 667 10 0.015
45 24 24 555 82 0.148 18 18 708 17 0.024
60 24 24 565 101 0.179 18 18 654 18 0.028
75 24 24 481 110 0.229 18 18 565 17 0.030
100 24 24 253 77 0.804 18 18 274 15 0.055
150 24 24 261 129 0.494 18 18 190 13 0.068
60 9 24 137 17 0.124 9 18 200 1 0.005
60 12 24 154 18 0.117 12 18 200 2 0.010
60 15 24 160 25 0.156 15 18 199 5 0.025
75 9 24 85 16 0.188 9 18 131 5 0.038
75 12 24 100 21 0.210 12 18 132 6 0.045
75 15 24 113 22 0.195 15 18 130 5 0.038
100 9 24 38 6 0.158 9 18 64 1 0.016
100 12 24 47 10 0.213 12 18 65 0 0.000
100 15 24 49 12 0.245 15 18 64 1 0.016
150 9 24 51 15 0.294 9 18 77 6 0.078
150 12 24 48 16 0.333 12 18 64 3 0.047
150 15 24 38 10 0.256 15 18 70 5 0.071
"A sacrifice at 18 months occurred only in riooms 144, 145, 146; a sacrifice at 24 months occuriried only in rooms 141, 142, 143.
'D represents close of2-AAF in parts per million; T, represents time oftermination ofdosingexpressed in months;T representstime of obser-
vation oftime-to-tumor onset distribution expressed in months.
'P is the nonparametric estimate ofthe probability oftumor onset by time T; X is the actual number oftumors observed up to time T; N=X/P is
the "effective" sample size.
within rooms (and, consequently, much of the data on
dead/moribund animals), it was decided to estimate time
to tumor distributions using combinations of three ani-
mal riooms, grouped according to common sacrifice time.
Although this approach confounds room differences with
evaluation time differences, it does provide a starting
Table 2. ED,, bladder tumor data adjusted for competing risks.
Rooms 141, 142, 143 combined" Rooms 144, 145, 146 combined"
D' T," T` N' X' P. T, T N X P
0 24 24 1176 8 0.007 18 18 1111 2 0.002
30 24 24 2179 17 0.008 18 18 1613 5 0.003
35 24 24 1628 7 0.004 18 18 1176 2 0.002
45 24 24 1043 12 0.012 18 18 952 6 0.006
60 24 24 652 6 0.009 18 18 294 3 0.010
75 24 24 699 16 0.023 18 18 488 2 0.004
100 24 24 220 38 0.173 18 18 255 13 0.051
150 24 24 329 264 0.802 18 18 337 179 0.531
60 9 24 152 3 0.020 9 18 184 0 0.000
60 12 24 198 4 0.020 12 18 190 0 0.000
60 15 24 116 0 0.000 15 18 196 1 0.005
75 9 24 78 1 0.013 9 18 128 2 0.016
75 12 24 130 2 0.015 12 18 132 0 0.000
75 15 24 106 2 0.019 15 18 131 1 0.008
100 9 24 35 0 0.000 9 18 64 1 0.016
100 12 24 43 2 0.047 12 18 67 2 0.030
100 15 24 46 2 0.043 15 18 64 0 0.000
150 9 24 48 9 0.188 9 18 63 4 0.063
150 12 24 52 18 0.346 12 18 64 15 0.234
150 15 24 49 21 0.429 15 18 68 25 0.368
"A sacrifice at 18 months occurred only in rooms 144, 145, 146; a sacrifice at 24 months occurred only in rooms 141, 142, 143.
"Drepresents dose of2-AAF in parts per million;T1 represents time oftermination ofdosingexpressed in months; T represents time ofobser-
vation oftime-tumor-onset distribution expressed in months.
'P is the nonparametric estimate ofthe probability oftumor onset by time T; X is the actual number oftumors observed up to time T; N=X/P is
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point for investigating potential lack of fit of models.
That is, if prediction of tumor rates for discontinued
dosing groups based on models fit to continuous dosing
data should break down due to room differences, it would
still be possible to perform such predictions individu-
ally for 18 and 24 months (i.e., within groups of rooms).
Whereas using tumor data from all six rooms taken
together overcomes the confoundingjust mentioned, any
model breakdown that might be due to room differ-
ences could not be so identified. Certainly for collapsed
data, tumor probability estimates at 18 months are
heavily influenced by the first three rooms and those at
24 months by the last three rooms.
Model Fitting
The nonlinear regression procedure (NLIN) in SAS
(18) was used for fitting various versions of the two-
stage model with cell proliferation to the tumor data in
Tables 1 and 2. Weighted least squares was employed,
with reciprocals of estimated variances being used for









where Pi and Ni are the values of the nonparametric
estimate of the probability of tumor onset by time T,
and the "effective" sample size, respectively, from Table
1 or Table 2 for the ith group; 1IN; is a correction for
continuity; Pi is the predicted probability of tumor,
1-exp {-H(D,T;0,T1)}, from the two-stage clonal expan-
sion model for the ith group; and m is the number of
distinct groups (distinct combinations of D, T, and T in
Table 1 or Table 2) used for fitting the model. Since the
sum of squares minimized is asymptotically a chi-square
random variable, the estimation method is a modified
minimum chi-square method.
Computationally, the Gauss-Newton method, the
Marquardt method, and the derivative-free multivariate
secant method (designated as DUD in NLIN) were used
to determine the direction and distance for each suc-
ceeding iteration. All parameters were constrained to
be nonnegative using BOUNDS statements.
To assess goodness-of-fit, a chi-square statistic like
the one minimized was used, except that predicted val-
ues ofPi obtained from the model, rather than observed
values, Pi, were used to calculate variances in the de-
nominator. Ifthe fit ofthe model to a set-ofdata points
used to estimate the model's parameters was being
assessed, then the degrees of freedom for chi-square
were calculated as the difference between the number
ofdata points and the number ofestimated parameters.
If the fit of the model to a separate set of data points
not used for fitting the model was being assessed, then
the degrees of freedom for chi-square were taken was
the number ofdata points.
Results for Two-Stage Clonal
Expansion Model
For each ofthe two tumor types, the first step was to
fit various versions ofthe model to all 40 data points in
order to ascertain which versions should be eliminated
and which warranted further investigation. Those
submodels of the general model that fit acceptably to
all the data points were further studied by fitting them
to only the 16 continuous dosing data points and then
assessing their predictive ability for the 24 discontinued
dosing data points, where possible.
For the liver tumor data (Table 1), the full, six-
parameter model fit acceptably to all 40 data points
(p = 0.76), as did the four-parameter initiator-promoter
model (p = 0.40) and the five-parameter initiator-
completer model (p = 0.70). All other submodels demon-
strated significant lack offit (p < 0.0001). The estimated
parameters of the six-parameter model are given in
Table 3, and the predicted probabilities of tumor are
presented in Table 4, where the observed probabilities
from Table 1 are reported for comparison purposes. As
stated previously in "Two-Stage Clonal Expansion Mo-
del," neither the full initiator-promoter-completer model
nor the initiator-completer model can be extrapolated
from a continuous to a discontinued dosing situation
due to a lack of identifiability of parameters. Thus the
only model left for such extrapolation was the initiator-
promoter model. That model gave an acceptable fit to
the 16 continuous dosing data points (p = 0.71) and also
fit well when extrapolated to the 24 discontinued dosing
data points (p = 0.68). However, as previously noted,
the continuous dosing version ofthe initiator-promoter
model is indistinguishable from the promoter-completer
model. And the promoter-completer model, as would be
expected since it did not flt the 40 data points initially,
demonstrated a signiflcant lack offlt when extrapolated
from the continuous to the discontinued dosing data
(p > 0.00001).
It is not possible to choose which, if any, of the three
models that flt acceptably to all 40 liver tumor data
points is the "correct" model. That is, the present bioas-
say data do not contain the refined biological information
necessary to choose one model over the others. In a
sense, it is gratifying that the full two-stage model with
colonal expansion, the initiator-promoter-completer
model, flts the data. However, it is not very satisfying
that two submodels, the initiator-promoter and initia-
tor-completer models, are approximately equally ac-
ceptable, since they represent two different biological
mechanisms. From a statistical point ofview, the initia-
tor-promoter model might be preferred, since it has the
fewest parameters and since it was possible to demon-
strate for that model successful extrapolation from the
continuous to the discontinued dosing situation. The
importance ofdiscontinued dosing experiments is high-
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Table 3. Estimated parameters ofthe six-parameter, two-stage clonal expansion model fitted to liver
and bladder tumor data.
Carcinogenic end point a, Pi aX2 aX P.",
Liver tumore 2.1 x 1O0i 2.1 x 10- 3.5 x 10-l 1.8 x 10-' 3.4 x 10-' 1.9 x 10-5
(1.8 x 10;)b (9.0 x 10 ) (0.0)c (5.4 x 104) (2.3 x 10-2) (8.6 x 10-)
Bladder tumor' 0.0 2.8 x10' 1.4 x 10-' 2.7 x 10' 1.9 x10W 2.7 x 10-'
(1.8 x 10-') (1.9 x 101) (9.2) (1.7 x 10-2) (9.0 x 10-') (6.0 x 10')
aGoodness-of-fit p-value = 0.76.
bEstimated SE in parentheses.
"Information matrix was singular.
"IGoodness-of-fit p-value < 0.00001.
Table 4. Comparison ofobserved and predicted probabilities ofliver tumor for the full, six-parameter,
two-stage clonal expansion model.
Rooms 141, 142, 143 combined' Rooms 144,145,146 combined',
D" T,"' Tb P (obs)' P (pred)' T, T P (obs) P (pred)
0 24 24 0.034 0.021 18 18 0.005 0.003
30 24 24 0.080 0.096 18 18 0.016 0.013
35 24 24 0.097 0.110 18 18 0.015 0.015
45 24 24 0.148 0.139 18 18 0.024 0.019
60 24 24 0.179 0.185 18 18 0.028 0.026
75 24 24 0.229 0.232 18 18 0.030 0.033
100 24 24 0.304 0.315 18 18 0.055 0.047
150 24 24 0.494 0.481 18 18 0.068 0.080
60 9 24 0.124 0.137 9 18 0.005 0.019
60 12 24 0.117 0.141 12 18 0.010 0.020
60 15 24 0.156 0.144 15 18 0.025 0.022
75 9 24 0.188 0.164 9 18 0.038 0.023
75 12 24 0.210 0.169 12 18 0.045 0.025
75 15 24 0.195 0.173 15 18 0.038 0.027
100 9 24 0.158 0.208 9 18 0.016 0.030
100 12 24 0.213 0.215 12 18 0.000 0.033
100 15 24 0.245 0.221 15 18 0.016 0.037
150 9 24 0.294 0.289 9 18 0.078 0.045
150 12 24 0.333 0.300 12 18 0.047 0.049
150 15 24 0.256 0.310 15 18 0.071 0.058
aA sacrifice at 18 months occurred only in rooms 144, 145, 146; a sacrifice at 24 months occurred only in rooms 141, 142, 143.
bD represents dose of 2-AAF in parts per million; T, represents time of termination of dosing expressed in months; T represents time of
observation oftime-to-tumor-onset distribution expressed in months.
eP (obs) is the nonparametric estimate ofthe probability oftumor onset from Table 1. P (pred) is the predicted probability oftumor onset from
the two-stage colonal expansion model.
lighted bythe rejection ofthe promoter-completer model
based on the discontinued dosing data, whereas that
model is indistinguishable with continuous dosing data
from the very successful but mechanistically very dif-
ferent initiator-promoter model.
For the bladder tumor data (Table 2), none of the
seven versions ofthe two-stage clonal expansion model
fit acceptably (p < 0.00001), whether all 40 data points
orjust the 16 continuous dosing data points were used.
Table 3 gives the estimated parameters for the full, six-
parameter model fitted to the 40 data points in Table 2.
The predicted probabilities of tumor for the six-
parameter model are given in Table 5, along with the
observed probabilities from Table 2.
It is quite disappointing that the two-stage clonal ex-
pansion model would not fit even the 16 continuous dos-
ing data points. Several possible remedies were inves-
tigated in an attempt to achieve an acceptable fit ofthe
model to these data. The pharmacokinetic dose trans-
formation ofWhittemore et al. (19), d' = aldk (1 + a2dk),
was tried for k = 1,2, which resulted in the estimation
of one additional parameter (a2). This is the familiar
Michaelis-Menten transformation when k = 1. A power
transformation, do = dk, also was attempted for k = 2 to
4. This was used first throughout the full model and
then only in the cell proliferation function. None ofthese
remedies provided an appreciable improvement in the
fit ofthe model.
It has been the experience ofother investigators with
other mechanistically derived models that the EDO, liver
tumor data are consistent with a variety ofsuch models
(5,6), but that the EDO1 bladder tumor data are not ad-
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Table 5. Comparison ofobserved and predicted probabilities ofbladder tumor for the full, six-parameter,
two-stage clonal expansion model.
Rooms 141,142,143 combined' Rooms 144, 145,146 combineda
Db T Tb P (obs)Y P(pred)c T, T P(obs) P(pred)
0 24 24 0.007 0.000 18 18 0.002 0.000
30 24 24 0.008 0.007 18 18 0.003 0.003
35 24 24 0.004 0.010 18 18 0.002 0.004
45 24 24 0.012 0.018 18 18 0.006 0.007
60 24 24 0.009 0.041 18 18 0.010 0.014
75 24 24 0.023 0.091 18 18 0.004 0.026
100 24 24 0.173 0.316 18 18 0.051 0.071
150 24 24 0.802 0.999 18 18 0.531 0.457
60 9 24 0.020 0.009 9 18 0.000 0.006
60 12 24 0.020 0.014 12 18 0.000 0.009
60 15 24 0.000 0.020 15 18 0.005 0.012
75 9 24 0.013 0.013 9 18 0.016 0.009
75 12 24 0.015 0.023 12 18 0.000 0.015
75 15 24 0.019 0.037 15 18 0.008 0.021
100 9 24 0.000 0.026 9 18 0.016 0.018
100 12 24 0.047 0.052 12 18 0.030 0.033
100 15 24 0.043 0.096 15 18 0.000 0.053
150 9 24 0.188 0.087 9 18 0.063 0.059
150 12 24 0.346 0.229 12 18 0.234 0.145
150 15 24 0.429 0.503 15 18 0.368 0.299
aA sacrifice at 18 months occurred only in rooms 144,145, 146; a sacrifice at 24 months occurred only in rooms 141, 142, 143.
bD represents dose of 2-AAF in parts per million; T, represents time of termination of dosing expressed in months; T represents time of
observation oftime-to-tumor-onset distribution expressed in months.
'P (obs) is the nonparametric estimate ofthe probability oftumor onset from Table 2. P (pred) is the predicted probability oftumor onset from
the two-stage clonal expansion model.
equately described by any ofthem (6,7). It appears that
the two-stage clonal expansion model as formulated in
this paper may be characterized the same way. For this




The model to be proposed here is more empirically
based than biologically based. Although the Weibull
distribution can arise naturally in the theory of sys-
tems reliability, its application to biological problems
has consisted mostly of empirical curve fitting. In the
analysis oftoxicity data, both dose and time have been
modeled separately as Weibull random variables. When
dose and time have appeared together in Weibull-type
models, generally time has been considered the random
variable (20). The commonly used continuous dosing
version of the multistage model of Armitage and Doll
(4) may be considered a Weibull model in time, with
the polynomial function in dose representing a scale
parameter.
Peto et al. (20) used two versions of a Weibull model
to describe carcinogenesis data on nitrosamines in a
study with a large number of rodents. In this discus-
sion, these two models will be distinguished according
to whether background is modeled as "additive" or "in-
dependent." The cumulative hazard for the additive
background model is
B(d,t) = (Zj)V t'L
and that for the independent background model is
KI(d,t) = (0dV) tk 9
where a, f, w, and k are all nonnegative constants. For
liver tumors that occurred under a continuous dosing
regimen, Peto et al. (20) found that the additive back-
ground model described the data best, there being an
appreciable background incidence of liver tumors. For
esophageal tumors observed under continuous dosing,
Peto et al. (20) found that the independent background
model fit best; in fact, the observed background inci-
dence ofesophageal tumors was zero, so that a was zero
in the model for esophageal tumors.
The parallels between the nitrosamine-induced liver
tumors and the EDO1 study's 2-AAF induced liver tu-
mors and between the nitrosamine-induced esophageal
tumors and the EDO1 study's bladder tumors suggest
that a Weibull model with additive background might
fit the EDO1 liver tumor data and that a Weibull model
with independent background mightfit the EDO1 bladder
tumor data. But how does one generalize the Weibull
model to the discontinued dosing situation? Unlike
mechanistically derived models, the Weibull model does
not have a natural extension to discontinued dosing.
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One generalization ofthe Weibull model to discontin-
ued dosing was given by Carlborg (21). He modeled the
EDO, tumorprevalence datausing only what is described
above as the independent background model. His gen-
eralization to discontinued dosing included a component
for duration ofdosing, but did not account for when the
dosing occurred. Carlborg (21) successfully fit a five-pa-
rameter model to the EDO, liver tumor prevalence data,
excluding a portion ofthe low-response continuous dos-
ing data, but including all the discontinued dosing data.
However, Carlborg (21) did not fit the bladder tumor
data on dose and time simultaneously. Apparently, the
model would not fit.
Freedman and Navidi (6) looked briefly at fitting the
Weibull model to EDO, bladder tumor prevalence data.
They were unable to obtain an acceptable fit, but noted
atendency for the dose exponent, w, to exceed the time
exponent, k, which they noted to be inconsistent with
the multistage model. Freedman and Navidi (6) quoted
the argument of Brown and Hoel (22) that a factorable
hazard model (like the Weibull or multistage) will not
fit the continuous dosing bladder tumor data over all
dose and time points. Brown and Hoel (22) made a simi-
lar but weaker statement about the liver tumor data,
which Carlborg (21) was able to fit acceptably, along
with the discontinued dosing data, using a factorable
Weibull model. The model that will now be proposed is
a discontinued dosing extension of the Weibull model
used by Peto et al. (20).
First consider additive background. Assume initially
that dosing occurs only between time to and t1 and at a
constant rate, d. The model can easily be generalized to
multiple periods of constant exposure, as will be dis-
cussed later. Let X represent a latency parameter, that
is, a minimum amount oftime that must elapse before a
tumor can be observed. Suppose that to<. <ti. Then
U(d,t) 0 9 t < ir 9
and
D(d,t) (sd) (t-r)t, T < t < tit
where l has been replaced byP1i for notational purposes.
If administered dose is abruptly discontinued, there is
no reason to assume that the effective dose will imme-
diately vanish. To generalize to time t >ti, suppose that
the general form of H(d,t) is the same but that time to
tumor is increased by a location shift ofthe distribution
to the right and that the dose is effectively reduced by
a scale factor. That is, let
HI(d,t)
- (,p2d)v (t-'r-c)w , t1 < t
where c > 0 and P2 < P. In order for this generalization
to be valid, at time t1, the condition
(so-d)' (tl--s)'
- (c*kd)(t'c
must be satisfied. This implies that c must be equal to
(t1-t)[1 - t(a+Pjd)/(a + 12d)1w'k], which in turn implies that
v(d,t) = j(e*jSd)VA(t-tj)
+ (c.pd)V/k (t1-c)JI , t1 < t
This generalized Weibull model (with to < t < t1) can be
applied to the EDO1 liver and bladder tumor data. The
independent background version is derived similarly and
may be expressed as
O ,P t <-,
H(d,t) )k, X < t < ti
l(pdv) 1/kkt-tl)
+ (widv)1/k(t -r)Ik, t < t.
Other versions of this generalized Weibull model de-
pend on the relative magnitude of t with respect to to
and tl. For 0 < t < to, the additive background model has
B(d,t)
v k(to-r) + (c*ud) (t1-t0)
+ a*2d)v/k(t-tk)kst, t I
with an analogous expression forthe independent back-
ground model. If t1 < t, then the additive background
model's cumulative hazard is
H(d,t) = I(.02d)/k(t-¶)I
- (*02d)V(t-r)k
9 t, C t
with an analogous expression for the independent
background model. With regard to multiple periods of
constant exposure, the cumulative hazard can easily be
derived in the same way as for a single exposure pe-
riod. It will have a similar appearance, but with addi-
tional terms inside the bracketed expression raised to
the kth power.
Results for Weibull Discontinued
Dosing Model
For the liver tumor data (Table 1), the additive
background model fit acceptably to the 40 data points
(p = 0.43), as did the independent background model
(p = 0.63). The estimated value oft was essentially zero
(7.2 x 10-17) for the additive model, whereas the esti-
mated value was 0.81 for the independent model. Pa-
rameter estimates for the additive model, for which the
prediction ofbackground tumor rates was slightly bet-
ter, are given in Table 6. The estimated power on dose
(w = 1.7) and the estimated power on time (k = 7.7) are
reasonably close to values (2 and 7, respectively) found
by Freedman and Navidi (6) for the dose and time
powers in the multistage model. Table 7 compares the
predicted probabilities of the six-parameter additive
background model to the observed probabilities from
Table 1.
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Table 6. Estimated parameters ofWeibull discontinued dosing models fitted to liver and bladder tumor data.
Carcinogenic end point Modeling ofbackground cc Pi P2 T w k
Liver tumora Additive 8.8 x 10- 2.8 x 10-" 1.1 x 10-" 7.2 x 10-"7 1.7 1.7
(8.4 x 107)b (2.4 x 10 ) (9.6 x 10-) (1.3 x 10-' ) (1.3) (1.3)
Bladder tumor' Independent 1.1 x 10-" 1.8 x 10-" 9.1 x 10-'x 7.0 6.1 2.2
(2.8 x 104) (1.5 x 10-14) (1.2 x 10-')) (8.8) (0.7) (2.7)
aGoodness-of-fit p-value = 0.43.
bEstimated SE in parentheses.
cGoodness-of-fit p-value = 0.47.
For the bladder tumor data (Table 2), the indepen- background model to the observed probabilities from
dent background model fit acceptably to the 40 data Table 2.
points (p = 0.47), whereas the additive background The results in Tables 6, 7, and 8 indicate good fits and
model did not (p < 10-7). Practically all the lack offit of predictive ability of the given Weibull models within
the additive background model appeared to be in the the range ofobserved doses (D), stoppingtimes (T1), and
background itself. Parameter estimates for the inde- observation times (T). In order to evaluate the predic-
pendent model are given in Table 6. The relative mag- tive ability ofthe models at points outside the range of
nitudes of the estimated power on dose (w = 6.1) and data used for fitting, observation times T = 15 and 33
the estimated power on time (k = 2.2) are inconsistent for continuous dosing were selected for prediction. The
with a multistage formulation in administered dose results are given in Table 9. The 15-month predictions
(wherein the power on time must equal or exceed the appear consistent with the observed data, which is it-
power on dose), a phenomenon noted by Freedman selfcharacterized by considerable variability about the
and Navidi (6) in reference to Carlborg (21). The same is lower dose rates. However, at 33 months the predic-
true for the two-stage model with clonal expansion; tions appear to break down. The liver tumor model is
however, in both cases, a judicious transformation of characterized by overprediction at the middle dose lev-
dose might improve the fit. Table 8 compares the pre- els, while the bladder tumor model is characterized by
dicted probabilities of the six-parameter independent substantial underprediction at 75 and 100 ppm.
Table 7. Comparison ofobserved and predicted probabilities ofliver tumor for the six-parameter Weibull
model with additive background.
Rooms 141, 142,143 combineda Rooms 144, 145,146 combined&
Db T,h Tb P (obs)Y P (pred)c T, T P (obs) P (pred)
0 24 24 0.034 0.031 18 18 0.005 0.003
30 24 24 0.080 0.095 18 18 0.016 0.011
35 24 24 0.097 0.108 18 18 0.015 0.012
45 24 24 0.148 0.135 18 18 0.024 0.016
60 24 24 0.179 0.180 18 18 0.028 0.021
75 24 24 0.229 0.227 18 18 0.030 0.027
100 24 24 0.304 0.310 18 18 0.055 0.040
150 24 24 0.494 0.477 18 18 0.068 0.068
60 9 24 0.124 0.110 9 18 0.005 0.014
60 12 24 0.117 0.122 12 18 0.010 0.016
60 15 24 0.156 0.135 15 18 0.025 0.019
75 9 24 0.188 0.135 9 18 0.038 0.018
75 12 24 0.210 0.150 12 18 0.045 0.020
75 15 24 0.195 0.167 15 18 0.038 0.024
100 9 24 0.158 0.178 9 18 0.016 0.024
100 12 24 0.213 0.200 12 18 0.000 0.028
100 15 24 0.245 0.225 15 18 0.016 0.034
150 9 24 0.294 0.271 9 18 0.078 0.039
150 12 24 0.333 0.307 12 18 0.047 0.047
150 15 24 0.256 0.346 15 18 0.078 0.057
aA sacrifice at 18 months occurred only in rooms 144, 145, 146; a sacrifice at 24 months occurred only in rooms 141, 142, 143.
bD represents dose of 2-AAF in parts per million; T, represents time of termination of dosing expressed in months; T represents time of
observation oftime-to-tumor onset distribution expressed in months.
cp (obs) is the nonparametric estimate ofthe probability oftumor onset from Table 1. P (pred) is the predicted probability oftumor onset from
the Weibull discontinued dosing model.
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Table 8. Comparison ofobserved and predicted probabilities ofbladder tumor for the six-parameter Weibull model with
independent background.
Rooms 141, 142, 143 combined, Rooms 144, 145,146 combineda
DI) Tl," Tb P (obs) P(pred)' T, T P(obs) P(pred)
0 24 24 0.007 0.005 18 18 0.002 0.002
30 24 24 0.008 0.005 18 18 0.003 0.002
35 24 24 0.004 0.005 18 18 0.002 0.002
45 24 24 0.012 0.006 18 18 0.006 0.002
60 24 24 0.009 0.012 18 18 0.010 0.005
75 24 24 0.023 0.030 18 18 0.004 0.012
100 24 24 0.173 0.140 18 18 0.051 0.057
150 24 24 0.802 0.825 18 18 0.531 0.491
60 9 24 0.020 0.006 9 18 0.000 0.002
60 12 24 0.020 0.007 12 18 0.000 0.003
60 15 24 0.000 0.008 15 18 0.005 0.004
75 9 24 0.013 0.008 9 18 0.016 0.004
75 12 24 0.015 0.012 12 18 0.000 0.006
75 15 24 0.019 0.015 15 18 0.008 0.008
100 9 24 0.000 0.020 9 18 0.016 0.010
100 12 24 0.047 0.036 12 18 0.030 0.021
100 15 24 0.043 0.056 15 18 0.000 0.037
150 9 24 0.188 0.162 9 18 0.063 0.086
150 12 24 0.346 0.296 12 18 0.234 0.198
150 15 24 0.429 0.447 15 18 0.368 0.339
aA sacrifice at 18 months occurred only in rooms 144, 145, 146; a sacrifice at 24 months occurred only in rooms 141, 142, 143.
hD represents dose of 2-AAF in parts per million; T, represents time of termination of dosing expressed in months; T represents time of
observation oftime-to-tumor-onset distribution expressed in months.
cP (obs) is the nonparametric estimate ofthe probability oftumor onset from Table 2. P (pred) is the predicted probability oftumor onset from
the Weibull discontinued dosing model.
Table 9. Prediction oftumor probabilities at 15 and 33 months based on models fitted to 18- and 24-month observations.
Tumor type
Liver Bladder
DIt T;' P1(obs)W P2(obsy)" P (pred)" PI(obs) P,(obs) P (pred)
0 15 0.000 0.001 0.001 0.007 0.001 0.001
30 15 0.000 0.009 0.003 0.005 0.000 0.001
35 15 0.010 0.000 0.003 0.004 0.000 0.001
45 15 0.000 0.010 0.004 0.001 0.005 0.001
60 15 0.007 0.000 0.005 0.000 0.000 0.002
75 15 0.000 0.000 0.007 0.014 0.000 0.006
100 15 0.023 0.012 0.010 0.000 0.003 0.029
150 15 0.016 0.007 0.017 0.263 0.313 0.287
0 33 0.322 0.507 0.303 0.007 0.036 0.013
30 33 0.653 0.627 0.686 0.040 0.020 0.013
35 33 0.551 0.681 0.735 0.004 0.006 0.014
45 33 0.659 0.691 0.816 0.086 0.050 0.016
60 33 0.663 0.825 0.900 0.009 0.111 0.029
75 33 1.000 0.748 0.950 0.512 0.333 0.074
100 33 1.000 0.867 0.987 1.000 1.000 0.316
150 33 1.000 0.879 0.999 1.000 1.000 0.988
iD represents dose of2-AAF in parts per million; T represents time ofobservation oftime-to-tumor-onset distribution expressed in months.
hPi(obs) isthenonparametric estimate oftheprobability oftumoronsetbytime Tbased ondatafrom rooms 141,142, 143 combined;P2(obs)isthe
correspondingestimatefrom rooms 144,145,146combined; P (pred) is the predicted probabilityoftumor onsetfromthe Weibull models described
in Table 6.
Discussion
It is disappointing that the two-stage model with pro-
liferation of initiated cells would not fit the bladder tu-
mor data from the EDO1 study. The experience here, like
that ofprevious investigators (6,7,22), indicates that the
relationship between dose of 2-AAF and time to blad-
der tumor might be too complex to be explained by
mechanistic models so far postulated. In the present
case, even allowing for the Michaelis-Menten and other
transformations of the administered dose, an accept-
able fit was not obtained.
The fact that the two-stage clonal expansion model
did fit the EDO1 study's liver tumor data is interesting
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and helps to narrow down the possible characteriza-
tions of liver carcinogenesis within the context of the
two-stage clonal expansion model. Although a complete
characterization was not possible, at least the simplest
notions of pure initiator, pure promoter, and pure com-
pleter could be eliminated. The importance of discon-
tinued dosing experiments is highlighted by the fact
that the promoter-completer model was rejected, while
the initiator-promoter model was not, the two models
being indistinguishable for continuous data only. It is
probably not advisable to make too much of the two-
stage clonal expansion model's fit to the liver tumor
data. For one thing, various other models have piro-
vided equally acceptable fits. For another, the model's
failure to fit the bladdcer tumor data makes its biologi-
cal interpretation less compelling.
With respect to the Weibull-type model that (lid fit
acceptably to the 18- and 24-month data on both liver
and bladder tumors, what conclusions can be drawn?
Unfortunately, this model too broke down when ex-
trapolated to tumor probabilities at 33 months. How-
ever, the good fits to the discontinued dosing data an(l
the successful extrapolation to 15 months of continuous
dosing give confidence that good predictions can be ma(le
for both liver and bladdcer tumor probabilities up to 24
months, regardless of when dosing stops. The impor-
tance of discontinued dosing experiments is again em-
phasized. Whether a model is mechanistically based or
simply empirically based, its ability or inability to ex-
plain discontinued dosing tumor data will priovide a good
measure of its predictive capability beyond the experi-
mental setting.
In addition to the discontinued dosing version of the
Weibull-type model presented here, there are other
formulations that might be useful. One such model that
was investigated in this study but not reported had
only four parameters. Instead of the additional scale
parameter 12 being introduced, the original parameter
13 was retained, but the dose was transformed to the
time-weighted-average dose. This model gave an ac-
ceptable fit for both liver and bladdeer tumors. How-
ever, the bladder tumor fit was not as good as that of
the model reported here. The advantage ofsuch a model
would be its extrapolation potential to discontinued
dosing situations based on parameters estimated firom
only continuous dosing data.
We are grateful to Scott Jordan an(l Charles McCarty ofComputerl
Base(d Systems, Inc. for their assistance with this project. We thank
Susan Taylor for typing the manuscriipt.
Appendix
Derivation ofHazard Function ofTwo-
Stage Clonal Expansion Model for Single,
Less-Than-Lifetime Period ofDosing
Assume that dosing occurs at a constant rate d be-
tween time to and ti, and is zero otherwise, and that the
experiment continues until time t, where 0 < t. < t1 <t.
Then the instantaneous hazard is
h(d,w;to,tl) =
w w
a2 JNa oexp {fa3duIdv
0 v
a1an











+ (a2 + 32d)f N(a, + 31d)exp{f (a3 +P3d)du) dv
to v
al(a2 +P2d)
N N ( exp(a3+±3d)(w-tO)l [exp(a3t0)-1]
a3
+ N1 +131d)(a2 2d) [expf(a3 +,3d)(w -to)) - 1],
a3 + wt
to ' w ' t1.
h(d,w;tot1) =
to to
a2f Na1 cxp{fa3 du
0 v
tl w
+ f (a3 +133d)du+Ja3 du) dv
to ti
ti ti w
+ a2fN(ai +1d) exp{J(a3 + 3d) du+Ja3 du) dv
to V t1
w w
+ a2JNa1 exp{ Ja3 du) dv
ti v
ala2
= N exp2(a3+ 3d)(t1 -to) + a3(w -t)l
a3
[exp(a3tA)- 11
+ N (e+f3ld) 2 exP(a3(w-t)l
aC3 +f33d
[exp{(a3 +P3d)(t1 -to)) -1]
+ N [exp{a3(w-t3)l-l], t1 < w.
a3
Of primary interest in this paper is the cumulative
hazard function for t1 < t. This is found by summing
together the integrals ofthe above three instantaneous
hazards, where the limits of integration on w are,
respectively, 0 to t(, to to ti, and t1 to t. The resulting
expression is
H(d,t;to,t1) = N 122 [exp(a3to)- 1-a3tO]
a3
a2 + 2d a
3+ ad -[exp(a3to)-1]
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[expf(oc3 T NdU)(t1 t)) 11
a1 +d
+ .[exp{(Q3 +[33d)(t1 -to)) - 1 -(a3 +133d)
OC3 + d
1 a2 [a (t -to)] +N( N-l exp[((a3+P13d)(tj-to))
C3 a3
[exp(oc3t0)-1] [exp{a3(t-tl))-1]
+ l1x+ a [expf3 - +d)(t to))-1 aC3 +033d
+ C [exp{a 3(t1td)1-l] C3(t-td , <t.
REFERENCES
1. Littlefield, N. A., Farmer,J. H.,Gaylor, D. W.,and Sheldion, W. G.
Effects of (lose an(I time in a long-term, low-dlose carcinogenic
study. J. Environ. Pathol. Toxicol. 3: 17-34 (1980).
2. Littlefield, N. A., Greenman, D. L., Far-mer,J. H., an(I Sheldon, W.
G. Effects ofcontinuous and (liscontinuedi exposure to 2-AAF on
urinary bladder hyperplasia an(d neoplasia. J. Enxviron. Pathol.
Toxicol. 3: 35-54 (1980).
3. Day. N. W., an(d Brown, C. C. Multistage modlels an(I primary
prevention ofcancer. J. Natl. Cancer Inst. 64: 977-989 (1980).
4. Ar-mitage, P.,an(d Doll, R.Stochastic modelsfoi carcinogenesis. In:
Proceedlings ofthe Fourth Berkeley Symposium on Mathematical
Statistics andl Probability, Vol. 4, Univeersity of California Press,
Berkeley, CA 1961, pp. 19-38.
5. Brown, K. G., and Hoel, D. G. Multistage prediction of cancer in
ser-ially dlose(l animals with application to the ED., Stu(dy. Fun-
dam. Appl. Toxicol. 3: 470-477 (19813).
6. Free(dman, D. A., and Navidi, W. C. Multistage mo(lels for
carcinogenesis. Environ. Health Perspect. 81: 169-188 (1989).
7. Chiang, C. L.,and Conforti, P. M. A survival model an(d estimation
oftime to tumor. Math Biosci. 94: 1-29 (1989).
8. Moolgavkei, S. H., andl Venzon, D. J. Two-event models for
carcinogenesis: incidence curves for childhood and adult tumors.
Math. Biosci. 47: 55-77 (1979).
9. Greenfield, R. E., Ellwein, L. B., and Cohen, S. M. A general
plrobabilistic model of carcinogenesis: analysis of experimental
urinary bladder cancer. Carcinogenesis 5: 437-445 (1984).
10. Thorslund, T. W., Brown, C. C., and Charnley, G. Biologically
motivated cancer risk models. Risk Anal. 7: 109-119 (1987).
11. Moolgavkar, S. H., and Knudson, A. G. Mutation and cancer:
a model for human carcinogenesis. J. Natl. Cancer Inst. 66:
1037-1052 (1981).
12. Bogen, K. T. Cell prioliferation kinetics and multistage cancer risk
models. J. Natl. Cancer Inst. 81: 267-277 (1989).
13. Armitage P., and Doll, R. A two-stage theory ofcarcinogenesis in
rielation to the age distribution ofhuman cancer. Br. J. Cancer 11:
161-169 (1957).
14. Chen, J. J., Kodell, R. L., and Gaylor, D. W. Using the biological
two-stage model to assess risk from short-term exposures. Risk
Anal. 8: 223-230 (1988).
15. Kodell, R. L.,Shaw,G.W.,andJohnson,A.M.Nonparametricjoint
estimators for disease resistance and survival functions in surviv-
al/sacrifice experiments. Biometrics 38: 43-58 (1982).
16. Dinse, G. E., and Lagakos, S. W. Nonparametric estimation of
lifetime and disease onset distributions from incomplete observa-
tions. Biometrics 38:921-932 (1982).
17. Turnbull, B. W., andl Mitchell, T. J. Nonparametric estimation of
the distribution oftime to onset for specific diseases in survival/
sacrifice experiments. Biometrics 40: 41-50 (1984).
18. SAS User's Guide: Statistics, Version 5 Edition. SAS Institute,
Inc., Cary, NC, 1985.
19. Whittemore,A.S.,Grossner,S.C.,andSilvers,A.Pharmacokinetics
inlowdoseextrapolationusinganimal cancerdata. Fundam.Appl.
Toxicol. 7: 183-190 (1986).
20. Peto, R., Gray, R. Brantom, P. and Grasso, P. Nitrosamine
carcinogenesis in 5120rodents. In: N-Nitroso Compounds: Occur-
rience, Biological Effects and Relevance to Human Cancer, Scien-
tificPublication No.57(J. K. O'Neill, R. C. vonBorstel, C.T.Miller,
J. Long,and H.Vartsch, Eds.), International AgencyforResearch
on Cancer, Lyon, 1984, pp. 627-665.
21. Carlborg, R. W. 2-Acetylaminofluorene and the Weibull model.
Fd. Cosmet. Toxicol. 19: 367-371 (1981).
22. Brown, K. G., and Hoel, D. G. Modeling time-to-tumor data: ana-
lysis ofthe ED01 Study. Fundam. Appl. Toxicol. 3:458-469 (1983).
23. Cohen, S. M., and Ellwein, L. B. Proliferative and genotoxic
cellular effects in 2-acetylaminofluorene bladder and liver car-
cinogenisis: biological modeling of the ED1,, study. Toxicol.
Appl. Pharmacol. 104: 79-93 (1990).